Advertisement
Advertisement
KYTX
Kyverna Therapeutics, Inc. Common Stock
7.54
USDSponsored
-0.08
-1.10%
Feb 05, 10:11 UTC -5
Open
KYTX Earnings Reports
Positive Surprise Ratio
KYTX beat 5 of 8 last estimates.
63%
Next Report
Date of Next Report
Mar 25, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/-$0.87
Implied change from Q3 25 (Revenue/ EPS)
--
/+2.35%
Implied change from Q4 24 (Revenue/ EPS)
--
/-1.14%
Kyverna Therapeutics, Inc. Common Stock earnings per share and revenue
On Nov 12, 2025, KYTX reported earnings of -0.85 USD per share (EPS) for Q3 25, beating the estimate of -0.99 USD, resulting in a 14.24% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -11.60% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 analysts forecast an EPS of -0.87 USD, with revenue projected to reach -- USD, implying an increase of 2.35% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.82
Actual
$11.44
Surprise
+5.65%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Twist Bioscience Corporation Common Stock
Report Date
Feb 02, 2026 For Q1 26
Estimate
-$0.43
Actual
-$0.50
Surprise
-14.00%
Mesoblast Limited - ADR
Report Date
Jan 29, 2026 For Q1 26
Estimate
-$0.06
Actual
-$0.07
Surprise
-5.90%
AYTU BioPharma, Inc. Common Stock
Report Date
Feb 03, 2026 For Q2 26
Estimate
-$0.61
Actual
-$1.05
Surprise
-71.57%
FAQ
What were Kyverna Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Kyverna Therapeutics, Inc. Common Stock reported EPS of -$0.85, beating estimates by 14.24%, and revenue of $0.00, 0% as expectations.
How did the market react to Kyverna Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -11.6%, changed from $7.33 before the earnings release to $6.48 the day after.
When is Kyverna Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 25, 2026.
What are the forecasts for Kyverna Therapeutics, Inc. Common Stock's next earnings report?
Based on 8
analysts, Kyverna Therapeutics, Inc. Common Stock is expected to report EPS of -$0.87 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement